Dr. Mary Pinder of Moffitt Cancer Center reviews the CUSTOM trial, in which the study of molecular markers was expanded to patients with small cell lung cancer and thymic carcinomas.

[powerpress]

Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nintedanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.

[powerpress]

Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.

[powerpress]

Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.

[powerpress]

Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.

[powerpress]

Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the POINTBREAK trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.

[powerpress]

Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta. 

[powerpress]

Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.

[powerpress]

Drs. Nate Pennell from Cleveland Clinic and Mary Pinder from Moffitt Cancer Center in Tampa, FL sat down with our own Dr. Jack West to discuss early impressions of some of the most provocative research presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago in early June.

Here's a growing list of podcasts covering the topics they discussed:

Is it possible to test for biomarkers in lung cancer on a national scale?